Ondine Biomedical Inc.

1. 30 Sep 26
   Capital Access Window - Ondine Biomedical Inc.

   COMMON SHARES OF NO PAR VALUE, FULLY PAID (CDI)

   RNS 9798421 ↗
2. 30 Sep 26
   Capital Access Window

   (AIM: OBI), a leader in light-activated antimicrobial therapies for the prevention and treatment of hospital infections, announces its intention to utilise AIM’s new Capital Access Window in connection with a proposed equity capital raise (the “Proposed...

   RNS 9797744 ↗
3. 30 Sep 26
   2026 Interim Results & Post-Period Momentum

   Ondine Biomedical Reports H1 2026 Results Following Positive Phase 3 Topline Readout and Continued Commercial Progress

   RNS 9797683 ↗
4. 29 Sep 26
   Ondine and Mela Advance NHS ICU Market Access

   Ondine Biomedical Leverages Mela Solutions' 90% NHS ICU Footprint to Advance Commercial Evaluation and Quantify Steriwave® Financial Impact

   RNS 9795283 ↗
5. 23 Sep 26
   Steriwave Deploys in 5 Southern Ontario Hospitals

   Five Southern Ontario Hospitals to Deploy Steriwave® Across Approximately 5,000 Annual Surgical Procedures

   RNS 9785657 ↗
6. 10 Sep 26
   Investor Presentation of Phase 3 Topline Results

   Ondine Biomedical to Present Topline Results from Phase 3 LANTERN Trial

   RNS 9764382 ↗
7. 07 Sep 26
   Largest Private Mexican Network Pilots Steriwave

   Hospitales Ángeles Health System Pilots Steriwave® Nasal Photodisinfection in two flagship Mexican Hospitals

   RNS 9757612 ↗
8. 01 Sep 26
   Positive Topline Results in US Phase 3 Study

   Ondine Biomedical Announces Positive Topline Results from Phase 3 Pivotal LANTERN Study

   RNS 9747539 ↗
9. 30 Jul 26
   Major Scottish Hospital Adopts Steriwave

   UK's Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection

   RNS 9694727 ↗
10. 13 Jul 26
    Update on US Phase 3 Pivotal Study

    (AIM: OBI), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, today provides an update on its LANTERN Phase 3 pivotal study evaluating the Company's non-antibiotic nasal photodisinfection technology (branded as...

    RNS 9664251 ↗
11. 01 Jul 26
    Keynote Address at 8th Annual Photodynamic Day

    Ondine Biomedical Keynote Address at 8th Annual Photodynamic Day in Türkiye

    RNS 9645718 ↗
12. 30 Jun 26
    Leeds drops SSI 78% over Mupirocin with Steriwave

    Published Leeds Study Shows Steriwave® Reduced Surgical Site Infections by 78% versus standard of care using Mupirocin in High Risk Endoscopic Endonasal Skull-Base Surgery

    RNS 9643058 ↗
13. 22 Jun 26
    Update on US Phase 3 Pivotal Study

    (AIM: OBI), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, today provides an update on its LANTERN Phase 3 pivotal study evaluating the Company's non-antibiotic nasal photodisinfection technology (branded as...

    RNS 9628754 ↗
14. 18 Jun 26
    Leeds Drops SSIs by 78.5% in Complex Brain Surgery

    Nasal Photodisinfection Reduces Surgical Infections in Complex Brain Surgery by 78.5% Compared to Nasal Antibiotics at Leeds Teaching Hospitals

    RNS 9624122 ↗
15. 04 Jun 26
    2025 Full Year Results and Annual Report

    Near-term Phase 3 pivotal study read out; growing international real-world evidence and commercial traction

    RNS 9600669 ↗
16. 26 May 26
    Steriwave ICU Study Outcomes Presented at CSRT2026

    SMURF Feasibility Study of Nasal Photodisinfection Presented at National Respiratory Conference

    RNS 9585683 ↗
17. 30 Apr 26
    Ondine Presented Steriwave Data at IPC 2026

    Ondine Biomedical Presented Steriwave Data at Recent Infection Prevention and Control Conference (IPC 2026)

    RNS 9546596 ↗
18. 29 Apr 26
    Result of Fundraise & TVR

    All references to C$ in this announcement ("Announcement") are to Canadian Dollars.

    RNS 9542932 ↗
19. 28 Apr 26
    Proposed c.£5 million (C$9.23 million) Fundraise

    THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY.

    RNS 9542619 ↗
20. 27 Apr 26
    ICU Study to be Presented at 2026 CACCN Conference

    Steriwave ICU Study Findings Selected for Oral Presentation at National Canadian Critical Care Nursing Conference

    RNS 9538217 ↗
21. 23 Apr 26
    Marked Reduction in SSIs at Ottawa Heart Institute

    University of Ottawa Heart Institute Reduces Surgical Site Infections Following Implementation of Steriwave Nasal Photodisinfection

    RNS 9533792 ↗
22. 22 Apr 26
    Two Abstracts Accepted at World Congress

    Ondine Biomedical Announces Selection of Two Abstracts for Presentation at the 2026 World Congress on Infectious Diseases

    RNS 9531562 ↗
23. 14 Apr 26
    Steriwave ICU Study Shows 39.5% Pneumonia Drop

    Pioneering research from Royal Columbian Hospital Foundation shows a significant decrease in pneumonia rates and establishes a new benchmark for ICU infection prevention.

    RNS 9518091 ↗
24. 13 Apr 26
    Business Update

    · Clinical Milestones: Completed patient enrolment in the pivotal LANTERN Phase 3 U.S. trial, with results expected in Spring 2026.

    RNS 9515719 ↗
25. 08 Apr 26
    ICU Study Accepted for Publication

    Ondine Biomedical and Royal Columbian Hospital Foundation Announce Major Research Milestone: First-of-its-Kind ICU Study Accepted by 'Journal of Critical Care'

    RNS 9509423 ↗
26. 10 Mar 26
    Ondine Provides Update on US Phase 3 Pivotal Study

    Ondine Provides Update on US Phase 3 Pivotal Study

    RNS 9465871 ↗
27. 25 Feb 26
    Share Issuance for ICU Study Submission

    Milestone-based Share Issuance Following Submission of Steriwave® ICU Study Results for Publication

    RNS 9445508 ↗
28. 06 Feb 26
    Ondine and Mid Yorks Win National Award

    Excellence in Healthcare Partnership Award recognises proven collaboration delivering significant SSI reductions and supporting NHS priorities

    RNS 9413666 ↗
29. 02 Feb 26
    Steriwave Up for 2025 “Product of the Year” Award

    Steriwave Up for 2025 "Product of the Year" Award

    RNS 9399928 ↗
30. 27 Jan 26
    Expanding Steriwave Use Across Vancouver Island

    Island Health's New Regional Powerhouse, Cowichan District Hospital, Adopts Steriwave to Lead Vancouver Island in Surgical Innovation

    RNS 9388104 ↗
31. 22 Jan 26
    Steriwave Expands into ENT Surgery in Spain

    (AIM: OBI), a leader in light-activated antimicrobial therapies, is pleased to announce the deployment of its Steriwave® nasal photodisinfection technology into a leading ear, nose and throat (ENT) specialist group operating surgical centres in Madrid and Málaga.

    RNS 9375855 ↗
32. 13 Jan 26
    New Independent Study Supports Photodisinfection

    Ondine Biomedical Provides Biological Context for Nasal Decolonization Strategies Following Landmark Nasal Microbiome Study

    RNS 9349075 ↗
33. 23 Dec 25
    Finalist for 2nd National Award for SSI reduction

    Finalist for 2nd National Award for SSI reduction

    RNS 9314250 ↗
34. 22 Dec 25
    First German Hospital Pilots Steriwave

    Ondine Biomedical Partners with LMU University Hospital Munich

    RNS 9311379 ↗
35. 16 Dec 25
    Ondine shortlisted for HSJ Partnership Award

    HSJ Partnership Award Finalists: Ondine Biomedical and Mid Yorkshire Teaching NHS Trust for Cutting Post-surgical Infection Rates

    RNS 9298704 ↗
36. 27 Oct 25
    Topline Results Significant in Steriwave ICU Study

    Steriwave Shows Significant Sustained ICU Pathogen Reduction in Royal Columbian Hospital Study Reinforcing Universal Nasal Decolonisation for Infection Control

    RNS 9195072 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.